MedTrace Logo

Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

NCT01427712 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2022-06-10

Study results available
· View outcomes & findings →

Summary

This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients due to cystic fibrosis receiving the treatment with LipaCreon in order to evaluate the effective and safe use of LipaCreon.

Conditions

Interventions

DRUG

Pancrelipase

Sponsors & Collaborators

  • Mylan Inc.

    lead INDUSTRY

Principal Investigators

  • Shigenori Haruna · Mylan EPD G.K.

Eligibility

Min Age
1 Year
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01427712 on ClinicalTrials.gov